# Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

> **NCT00771134** · PHASE2 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 105 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Lu AA39959
- **DRUG:** Placebo
- **DRUG:** Quetiapine

## Key facts

- **NCT ID:** NCT00771134
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2009-06
- **Final completion:** 2009-08
- **Target enrollment:** 105 (ACTUAL)
- **Why stopped:** Study was previously suspended and is now terminated
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00771134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00771134, "Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression". Retrieved via MORVS 2026-11-19 from https://api.morvs.ai/clinical/NCT00771134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
